Skip to main content

14-06-2021 | ASCO 2021 | Conference coverage | Video

Capecitabine remains the postoperative standard of care for TNBC with residual disease

Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy (4:01).

Read transcript

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits